Quest Diagnostics Raises 2026 Guidance After Strong Quarter

The laboratory provider saw double-digit revenue growth while navigating a recent data security breach.

Updated on Oct. 22, 2026 in Healthcare

Isometric editorial illustration of a glass test tube in a metal rack, symbolizing clinical diagnostics and operational precision. — Quest Diagnostics raised its full-year 2026 earnings guidance to between $11.25 and $11.35 per share following a 10% revenue increase. AI Illustration. Upload story photo >

Live Poll

Do you still trust large healthcare companies after they report a data security breach?

Quest Diagnostics reported third-quarter 2026 adjusted earnings of $3 per share alongside a 10% year-over-year revenue increase to $3.097 billion. Following these results, the company raised its full-year 2026 adjusted earnings guidance to between $11.25 and $11.35 per share.

Why it matters

Financial growth is fueled by the rising clinical care demands of an aging population and a renewed industry focus on preventative wellness measures. Despite the positive fiscal outlook, the company is managing a recent unauthorized access incident within its Quanum LSM system.

Adjusted operating income reached $517 million, representing a 13% increase from the prior year. While total requisition volume rose 14.5%, revenue per requisition declined by 4.2% compared to the same period in 2025.

The players

Quest Diagnostics

The company is a leading provider of diagnostic testing services and health information in the United States.

The details

Quest Diagnostics confirmed that an unauthorized party gained access to patient records stored in its Quanum LSM system. The company has implemented cybersecurity response procedures to contain the activity and notes that the event has not materially disrupted business operations.

2014: The Protecting Access to Medicare Act was enacted.
Q3 2026: Quest Diagnostics financial results were recorded for this period.
October 22, 2026: The financial report was published.
2027: This year marks the estimated impact window for PAMA regulatory changes.
2027-2029: This period covers the expected cumulative PAMA regulatory impact.

Market Landscape

Quest Diagnostics faces ongoing revenue pressure from the Protecting Access to Medicare Act, which has mandated lower payment rates for laboratory services since 2014. The firm continues to counter these regulatory headwinds by scaling automation and AI to improve operational productivity.

Customers should monitor for any specific safety or privacy advisories as the investigation into the Quanum LSM system incident continues. There are no immediate changes to service pricing or product availability for patients as a result of these quarterly financial results.

The takeaway

Quest Diagnostics continues to see strong demand for lab services driven by an aging population despite regulatory pricing pressures. The company is leaning into automation and AI to maintain margins while working to resolve a recent data security vulnerability.